Related Experiment Video
Updated: Sep 10, 2025
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Integrative genomic identification of therapeutic targets for pancreatic cancer
Jimmy A Guo1, Dennis Gong2, Kyle Evans3
1Broad Institute of MIT and Harvard, Cambridge, MA, USA; School of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, and new therapeutic strategies are urgently needed. Here, we conduct an integrative, genome-scale examination of genetic dependencies and cell surface targets using CRISPR-Cas screening and multi-omic data, including single-nucleus and spatial transcriptomic data from patient tumors. We systematically identify clinically tractable and biomarker-linked PDAC dependencies, including CDS2 as a synthetic lethal target in cancer cells expressing signatures of epithelial-to-mesenchymal transition. We examine biomarkers and co-dependencies of the KRAS oncogene, defining gene expression signatures of sensitivity and resistance associated with response to pharmacological inhibition of KRAS. mRNA and protein profiling reveal cell surface protein-encoding genes with robust expression in patient tumors and minimal expression in non-malignant tissues. Furthermore, we define intratumoral and interpatient heterogeneity of target gene expression and identify orthogonal targets that suggest combinatorial strategies. Collectively, this work identifies multiple targets that may inform therapeutic strategies for patients with PDAC.
Insights
New research identifies key genetic dependencies and cell surface targets for pancreatic cancer (PDAC). This study highlights potential therapeutic strategies and biomarkers for this deadly disease, offering hope for improved patient outcomes.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited therapeutic options.
- There is an urgent need for novel therapeutic strategies and drug targets for PDAC.
Purpose of the Study:
- To conduct a genome-scale examination of genetic dependencies and cell surface targets in PDAC.
- To identify clinically tractable targets and biomarkers for PDAC treatment.
Main Methods:
- Utilized CRISPR-Cas screening and multi-omic data, including single-nucleus and spatial transcriptomics.
- Analyzed genetic dependencies, cell surface protein expression, and KRAS oncogene co-dependencies.
Main Results:
- Identified CDS2 as a synthetic lethal target in PDAC cells with epithelial-to-mesenchymal transition signatures.
- Defined gene expression signatures for KRAS inhibitor sensitivity and resistance.
- Discovered cell surface protein-encoding genes with tumor-specific expression.
- Characterized intratumoral and interpatient heterogeneity of target gene expression.
Conclusions:
- This integrative genomic analysis provides multiple potential therapeutic targets for PDAC.
- Findings may inform the development of novel treatment strategies and combinatorial therapies for PDAC patients.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...